Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* ≥ 50 years of age and ≤ 75 years of age.~* De novo acute myelogenous leukemia (AML), based on FAB and WHO criteria.~* Intermediate or unfavorable cytogenetic abnormalities based on Southwest Oncology Group (SWOG) Cytogenetic Criteria.~* First morphologic complete remission (CR), or CRp (a complete remission but with low platelets) following 1 or 2 courses of induction therapy, documented no more than 8 weeks prior to the date of enrollment and confirmed at time of enrollment.~* Karnofsky Performance Score ≥ 60.~* Suitable for non-myeloablative transplantation or best treatment.~* Able to understand and willing to sign a written informed consent document.~EXCLUSION CRITERIA~* AML with favorable cytogenetic features based on SWOG Cytogenetic Criteria~* AML, either treatment-related or MDS-related~* Active CNS disease as identified by positive CSF cytospin at time of enrollment.~* Prior or concurrent malignancies except localized non-melanoma skin malignancies or treated cervical carcinoma in situ. (EXCEPTION: Cancer treated with curative intent \> 5 years previously is allowed. EXCEPTION: Low grade lymphoma is allowed as long as active treatment is not required for control of disease)~* Planned for allogeneic transplant using a full-dose conditioning~* Life expectancy \< 1 year due to diseases other than malignancy~* Pregnant or breastfeeding.~* HIV-seropositive.~* Uncontrolled infection (presumed or documented) with progression after appropriate therapy for greater than one month.~* Symptomatic coronary artery disease or uncontrolled congestive heart failure. Left ventricular ejection fraction (LVEF) is not required to be measured, however if measured, exclusion if ejection fraction is \< 30%.~* Requiring supplementary continuous oxygen. Diffusing capacity of the lungs for carbon monoxide (DLCO) is not required to be measured, however if it is measured, exclusion if DLCO \< 35%.~* Fulminant liver failure~* Cirrhosis with evidence of portal hypertension or bridging fibrosis~* Alcoholic hepatitis~* Esophageal varices~* A history of bleeding esophageal varices~* Hepatic encephalopathy~* Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time~* Ascites related to portal hypertension~* Chronic viral hepatitis with total serum bilirubin \> 3 mg/dL~* Symptomatic biliary disease

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Allo-HSCT + TLI + ATG (Type: EXPERIMENTAL): Participants achieving complete remission after consolidation therapy \& who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:~* Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)~* Anti-thymocyte globulin (ATG) Days -11 to -7~* Methylprednisolone Days -11 to -7~* Cyclosporine (CSP) Days -4 to +2~* 5+ of 6 HLA-matched CD34+ cells on Day 0~* Mycophenolate mofetil (MMF), Day 0 to Day +28
- Best Standard Care (Type: ACTIVE_COMPARATOR): Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:~* Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).